Evaluation of Genetic-molecular Causes of Out-of-Hospital Cardiac Arrest: From Patients to Families

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-50
SponsorFondazione IRCCS Policlinico San Matteo di Pavia

About this trial

The aims are to define the exact prevalence of hereditary heart diseases in out-of-hospital cardiac arrest (OHCA) patients taking also into account gender, patient and OHCA characteristics, provincial settings and environmental pollution; to stratify the individualized arrhythmic risk of proband's family members to prevent further sudden cardiac deaths; to refine the classification of the variants of uncertain significance (VUS) on genes which can have the capability to drive to molecular alterations leading to arrhythmogenic hereditary heart diseases. A blood sample will be obtained during resuscitation from all the patients aged ≤50 years suffering an OHCA in Lombardy Region and then analysed for genetic variants possibly causative of cardiac diseases. Genetic data will be merged with patient, OHCA and post-resuscitation data thanks to the connection with LombardiaCARe, whilst pollution data will be retrieved from ARPA Lombardia for free. A genetic counselling and clinical-instrumental evaluation of the proband's first-degree family members will be performed if a pathogenic/likely pathogenic variant or a VUS will be disclosed during the genetic analysis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

All the patients suffering from OHCA of medical etiology in Lombardy Region ≤50 years, for whom resuscitation manoeuvres was started by EMS (AREU)

Disqualifiers

Patients under 18 years old

Patients with a non-medical cause of the cardiac arrest

Trial population

All the patients suffering from OHCA of medical etiology in Lombardy Region ≤50 years, for whom resuscitation manoeuvres was started by EMS (AREU)

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

1,725 Participants
are grouped into 1 trial group
Group A: OHCA patients under 50 years

Trial outcomes

Primary outcomes

1

Prevalence of pathogenic/likely-pathogenic variants

Percentage of patients with pathogenic/likely-pathogenic variants or with variants of unknown significance (VUS) as defined by ACMG guidelines out of the total number of patients analysed

Time frame
December 2027

Secondary outcomes

1

Difference in prevalence according to different provinces

To evaluate whether the prevalence of inherited arrhythmogenic or structural cardiac diseases differs across the provinces of the Lombardy Region among patients aged ≤50 years with medically caused OHCA

Time frame
December 2027
2

Difference in prevalence according to the initial rhythm

To assess whether the prevalence of inherited arrhythmogenic or structural cardiac diseases differs according to the first documented cardiac rhythm (shockable vs. non-shockable)

Time frame
December 2027
3

Difference in prevalence across the various patient subgroups suggested by the Utstein recommendations and according to sex and level of pollutants

To investigate differences in the prevalence of inherited arrhythmogenic or structural cardiac diseases according to Utstein-recommended patient subgroups (witnessed shockable rhythm, shockable rhythm with bystander-initiated cardiopulmonary resuscitation, and witnessed non-shockable rhythm), as well as according to patient sex and levels of ambient air pollution in the area where the cardiac arrest occurred

Time frame
December 2027
4

Difference in treatment and survival in patients with and without variants

To compare treatment characteristics and survival to hospital arrival between patients in whom a pathogenic or likely pathogenic variant associated with inherited arrhythmogenic or structural cardiac disease is identified and those in whom no such variant is detected

Time frame
December 2027

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.